|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Recently approved and investigational antibiotics for treatment of severe infections caused by Gram positive bacteria显示文摘 | Appelbaum PC Jacobs MR | 2005 | Curr Opin Microbiol2005，8，5： | 1 |
| 2 | Acute lymphocytic leukemia: role of hematopoioetic stem cell transplantation in current management 显示文摘 | Irit A Jacob MR | 2003 | Curr Opin Hemato12003，10，： | 1 |
| 3 | Risk fac- tors or Contact lens bacterial contamination during continuous wear显示文摘 | Szczotka-Flynn LB Bajaksouzian S Jacobs MR | 2009 | Optom Vis Sci2009，86，11： | 1 |
| 4 | Postantibiotic effects of gatifloxacin against Gram-positive and negative organisms显示文摘 | Pankuch GA Jacobs MR Appelbaum PC | 1999 | Antimicrob Agents Chemother1999，43，12： | 1 |
| 5 | The Alexander project 1998-2000:susceptibility of pathogens isolated from community-acquired respiratory tract infection to com monly used antimicrobial agents显示文摘 | Jacobs MR Felmingham D Appelbaum PC | 2003 | J Antimicrob Chemother2003，52，2： | 1 |
| 6 | Influence of autonomic nervous system dysfunction on the development of type 2 diabetes:the CARDIA study显示文摘 | Camethon MR Jacobs DR Jr Sidney S | 2003 | Diabetes Care J2003，26，11： | 1 |
| 7 | The Alexander Project: the benefits from a decade of surveillance 显示文摘 | Felmingham D white AR jacobs Mr | 2005 | J Antimicrob Chemother2005，56，2： | 1 |
| 8 | Yersinia enterocolitica biotype 1 in South Africa显示文摘 | Robins-Browne RM Jacobs MR Koornhof HJ | 1979 | S Afr Med J1979，55，： | 1 |
| 9 | Susceptibilities of 177 penicillin susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxirae, ceftazidime, imipenem, biapenem, meropenem, and vancomycin 显示文摘 | Spangler SK Jacobs MR Appelbaum PC | 1994 | Antimicrob Agents Chemother1994，38，4： | 1 |
| 10 | Activity of nine oral agents against gram - positive and gram - negative bacteria encountered in community acquimd infections: use of pharmacokinetic/pharmacodynamic break- points in the comparative assessment of beta - lactam and macrolide an- timicrobial agents 显示文摘 | Peric M Browne FA Jacobs MR | 2003 | Clin Ther2003，25，1： | 1 |
| 11 | Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS 显示文摘 | Jablonski MR Jacob DA Campos C | 2012 | Neurobiol Dis2012，47，： | 1 |
| 12 | How can we predict bacterial eradication?显示文摘 | Jacobs MR | 2003 | Int J Infect Dis2003，8，1： | 1 |
| 13 | Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents显示文摘 | Pankuch GA Davies TA Jacobs MR | 2002 | Antimicrob Agents Chemother2002，46，： | 1 |
| 14 | Future directions for epilepsy research 显示文摘 | Jacobs MP Fischbach GD Davis MR | 2001 | Neurology2001，57，9： | 1 |
| 15 | Effects of amino acid alterations in penicillin-binding proteins(PBPs) 1a,2b and 2x on PBP affinities of penicillin,ampicillin,amoxicillin,cefditoren,cefuroxime,cefprozil,and cefaclor in 18 clinical isolates of penicillinsusceptible,-intermediate a显示文摘 | Nagai K Davies TA Jacobs MR | | 0，，： | 1 |
| 16 | Antimicrobial treatment guideline for acute bacterial rhinosinusitis 显示文摘 | Anon JB Jacobs MR Poole MD | 2004 | Otolaryngol Head Neck Surg2004，130，： | 1 |
| 17 | Bacterial contamina-tion of platelets显示文摘 | Palavecino EL Yomtovian RA Jacobs MR | 2010 | Transfus Apher Sci2010，42，1： | 1 |
| 18 | Effects of amino acid alterations in penicillin-binding protens(PBPs) 1 a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and-resistant pneumococci 显示文摘 | Nagai K Davies TA Jacobs MR | 2002 | Antimicrob Agents Chemother2002，46，： | 1 |
| 19 | Application of pharmacokinet- ics and pharmacodynamics to antimicrobial therapy of respiratory tract infections 显示文摘 | AndesD Anon J Jacobs MR | 2004 | Clin Lab Med2004，24，： | 1 |
| 20 | Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children 显示文摘 | JACOBS MR | 2007 | Future Microbiol2007，2，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员